| Screening | Baseline | COS-P group (intervention arm only) | 3-month f/u | 7-month f/u | 12-month f/u |
---|---|---|---|---|---|---|
Informed consent | X | X | Â | Â | Â | Â |
CORE-10 | X | Â | Â | Â | Â | Â |
Inclusion and exclusion criteria | Â | X | Â | Â | Â | Â |
Demographics | Â | X | Â | Â | Â | Â |
Randomisation | Â | X | Â | Â | Â | Â |
CORE-OM | Â | X | Â | X | X | X |
PBQ | X | X | Â | X | X | X |
CTQ-SF | Â | X | Â | Â | Â | Â |
DERS | Â | X | Â | X | X | X |
ASQ-SE | Â | X | Â | X | X | X |
ASQ-3 | Â | X | Â | X | X | X |
Sensitivity scales | Â | X | Â | X | X | X |
CSRI | Â | X | Â | X | X | X |
EQ-5D-5L | Â | X | Â | X | X | X |
CORE-6D | Â | X | Â | X | X | X |
SSP | Â | Â | Â | Â | Â | X |
Adverse events | Â | X | Â | X | X | X |
Short experience survey | Â | Â | X | Â | Â | Â |
Qualitative interviews | Â | Â | X | Â | Â | Â |